endTB clinical trial | Maelenn Gouillou

endTB clinical trial: results in key subgroups of patients with drug-resistant tuberculosis
Three experimental regimens (endTB1, endTB2, endTB3) were noninferior to the control in the primary analysis. The analysis presented here explores the efficacy results of the endTB clinical trial in key subgroups (HIV positive, low BMI, diabetes, severe disease) to help clinicians to make the choice between these three regimens for patients with a more difficult to treat form of disease.
All 3 arms could reasonably be used in patients with severe disease or diabetes. endTB1 and endTB2 appeared to be particularly efficacious in HIV positive patients. Longer or regimens with more drugs may achieve better results in patients with low BMI. Additional research is needed to confirm these findings.